Semin Neurol 2019; 39(02): 200-212
DOI: 10.1055/s-0039-1683380
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Interpretation of Biomarker Data in Diagnosis of Primary Dementias

Arash Salardini
1   Department of Neurology, Yale School of Medicine, New Haven, Connecticut
› Author Affiliations
Further Information

Publication History

Publication Date:
29 March 2019 (online)

Abstract

In the last few years, an improved understanding of dementia biomarkers has significantly increased the diagnostic accuracy for dementias. The National Institutes of Health Biomarkers Definitions Working Group defines a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” In the field of dementia, a biomarker is a biological measure pointing to a specific dementing pathology. Dementia biomarkers may also serve as surrogates for disease progression and as endpoints in clinical trials. Dementia biomarkers are best characterized for Alzheimer's disease, which is the most common form of primary dementia. The current “biological” conception of Alzheimer's disease is based on consideration of three biomarkers: amyloid, tau, and “neurodegeneration.” The status of these biomarkers may be determined by cerebrospinal fluid clinical chemistry or imaging. Biomarkers for other primary dementias are less reliable and rely chiefly on structural and functional imaging. When appropriate, genetic testing may help with diagnostic certainty in hereditary forms of dementia.

 
  • References

  • 1 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (03) 89-95
  • 2 Alzheimer's Association. 2018 Alzheimer's disease facts and figures. Alzheimers Dement 2018; 14: 367-429
  • 3 Larson EB. Minimizing excess disability: a common strategy for chronic disease management. J Geriatr Psychiatry Neurol 1997; 10 (02) 49-50
  • 4 Dawson P, Kline K, Wiancko DC, Wells D. Nurses must learn to distinguish between excess and actual disability to prolong the patient's competence. Geriatr Nurs (Minneap) 1986; 7: 298-300
  • 5 Atri A. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. Handb Clin Neurol 2016; 136: 971-984
  • 6 Plewes DB, Kucharczyk W. Physics of MRI: a primer. J Magn Reson Imaging 2012; 35 (05) 1038-1054
  • 7 Pasi M, Poggesi A, Pantoni L. The use of CT in dementia. Int Psychogeriatr 2011; 23 (Suppl. 02) S6-S12
  • 8 Jack Jr CR, Barnes J, Bernstein MA. , et al. Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement 2015; 11 (07) 740-756
  • 9 Harper L, Barkhof F, Scheltens P, Schott JM, Fox NC. An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry 2014; 85 (06) 692-698
  • 10 Ropper A, Samuels M, Klein J. Adams and Victor's Principles of Neurology. 10th ed. New York, NY: McGraw-Hill Education; 2014
  • 11 Yamada M. Cerebral amyloid angiopathy and gene polymorphisms. J Neurol Sci 2004; 226 (1–2): 41-44
  • 12 Pasquier F, Leys D, Weerts JGE, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 1996; 36 (05) 268-272
  • 13 Scheltens P, Leys D, Barkhof F. , et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55 (10) 967-972
  • 14 Jack Jr CR, Petersen RC, Xu YC. , et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49 (03) 786-794
  • 15 Chan D, Fox NC, Scahill RI. , et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol 2001; 49 (04) 433-442
  • 16 Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 2017; 13 (08) 457-476
  • 17 Rohrer JD, Ridgway GR, Crutch SJ. , et al. Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage 2010; 49 (01) 984-993
  • 18 Whitwell JL, Xu J, Mandrekar J. , et al. Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. Neurobiol Aging 2013; 34 (02) 636-639
  • 19 Lee SE, Rabinovici GD, Mayo MC. , et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70 (02) 327-340
  • 20 Rohrer JD, Clarkson MJ, Kittus R. , et al. Rates of hemispheric and lobar atrophy in the language variants of frontotemporal lobar degeneration. J Alzheimers Dis 2012; 30 (02) 407-411
  • 21 Koedam ELGE, Lehmann M, van der Flier WM. , et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011; 21 (12) 2618-2625
  • 22 Lehmann M, Koedam ELGE, Barnes J. , et al. Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiol Aging 2012; 33 (03) 627.e1-627.e12
  • 23 Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015; 372 (03) 249-263
  • 24 Righini A, Antonini A, De Notaris R. , et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol 2004; 25 (06) 927-932
  • 25 Persson K, Barca ML, Cavallin L. , et al. Comparison of automated volumetry of the hippocampus using NeuroQuant® and visual assessment of the medial temporal lobe in Alzheimer's disease. Acta Radiol 2018; 59 (08) 997-1001
  • 26 Koncz R, Sachdev PS. Are the brain's vascular and Alzheimer pathologies additive or interactive?. Curr Opin Psychiatry 2018; 31 (02) 147-152
  • 27 Wardlaw JM, Smith EE, Biessels GJ. , et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (08) 822-838
  • 28 Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry 2008; 64 (04) 273-280
  • 29 Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987; 149 (02) 351-356
  • 30 Nestor PJ, Altomare D, Festari C. , et al; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging 2018; 45 (09) 1509-1525
  • 31 Ortner MM. The use of 18F-FDG PET in the diagnostic workup of Alzheimer's dementia. Methods Mol Biol 2018; 1750: 213-219
  • 32 Naj AC, Jun G, Beecham GW. , et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43 (05) 436-441
  • 33 Fitzgerald DBD, Drago V, Jeong Y, Chang Y-LL, White KD, Heilman KM. Asymmetrical alien hands in corticobasal degeneration. Mov Disord 2007; 22 (04) 581-584
  • 34 Whitwell JL, Graff-Radford J, Singh TD. , et al. 18F-FDG PET in posterior cortical atrophy and dementia with Lewy bodies. J Nucl Med 2017; 58 (04) 632-638
  • 35 Iizuka T, Iizuka R, Kameyama M. Cingulate island sign temporally changes in dementia with Lewy bodies. Sci Rep 2017; 7 (01) 14745
  • 36 Kanda T, Ishii K, Uemura T. , et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2008; 35 (12) 2227-2234
  • 37 Jeong Y, Cho SS, Park JM. , et al. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med 2005; 46 (02) 233-239
  • 38 McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev 2015; 1: CD010633
  • 39 Scheltens P, Blennow K, Breteler MMB. , et al. Alzheimer's disease. Lancet 2016; 388 (10043): 505-517
  • 40 Imaging Dementia- Evidence for Amyloid Scanning. Available at: https://www.ideas-study.org/ . Accessed December 28, 2018
  • 41 Mallik A, Drzezga A, Minoshima S. Clinical amyloid imaging. Semin Nucl Med 2017; 47 (01) 31-43
  • 42 Simonsen AH, Herukka S-K, Andreasen N. , et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement 2017; 13 (03) 274-284
  • 43 Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O'Brien JT. In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev 2017; 36: 50-63
  • 44 Jack Jr CR, Bennett DA, Blennow K. , et al; Contributors. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14 (04) 535-562
  • 45 Sachdev P, Kalaria R, O'Brien J. , et al; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014; 28 (03) 206-218
  • 46 Loy CT, Schofield PR, Turner AM, Kwok JBJ. Genetics of dementia. Lancet 2014; 383 (9919): 828-840
  • 47 Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9 (02) 106-118
  • 48 Di Donato I, Bianchi S, De Stefano N. , et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Med 2017; 15 (01) 41
  • 49 First practice guidelines for clinical evaluation of Alzheimer's disease and other dementias for primary and specialty care. Available at: https://www.prnewswire.com/news-releases/first-practice-guidelines-for-clinical-evaluation-of-alzheimers-disease-and-other-dementias-for-primary-and-specialty-care-300684556.html . Accessed December 28, 2018